Abstract:In recent years, gene therapy has been raising hopes toward viable treatment strategies for rare genetic diseases for which there has been almost exclusively supportive treatment. We here review this progress at the pre-clinical and clinical trial levels as well as market approvals within diseases that specifically affect the brain and spinal cord, including degenerative, developmental, lysosomal storage, and metabolic disorders. The field reached an unprecedented milestone when Zolgensma® (onasemnogene abeparvovec) was approved by the FDA and EMA for in vivo adeno-associated virus-mediated gene replacement therapy for spinal muscular atrophy. Shortly after EMA approved Libmeldy®, an ex vivo gene therapy with lentivirus vector-transduced autologous CD34-positive stem cells, for treatment of metachromatic leukodystrophy. These successes could be the first of many more new gene therapies in development that mostly target loss-of-function mutation diseases with gene replacement (e.g., Batten disease, mucopolysaccharidoses, gangliosidoses) or, less frequently, gain-of-toxic-function mutation diseases by gene therapeutic silencing of pathologic genes (e.g., amyotrophic lateral sclerosis, Huntington's disease). In addition, the use of genome editing as a gene therapy is being explored for some diseases, but this has so far only reached clinical testing in the treatment of mucopolysaccharidoses. Based on the large number of planned, ongoing, and completed clinical trials for rare genetic central nervous system diseases, it can be expected that several novel gene therapies will be approved and become available within the near future. Essential for this to happen is the in depth characterization of short- and long-term effects, safety aspects, and pharmacodynamics of the applied gene therapy platforms.

A primer to gene therapy: Progress, prospects, and problems

Viral vector‐based gene therapies in the clinic

Prime Editing for Human Gene Therapy: Where Are We Now?

Recent Therapeutic Gene Editing Applications to Genetic Disorders

A new age of precision gene therapy

Clinical and Translational Landscape of Viral Gene Therapies

Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application

CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future

Engineering Gene Therapy: Advances and Barriers

Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets

Gene Therapy Leaves a Vicious Cycle

CRISPR-Cas9 gene editing technology in human gene therapy: the new realm of medicine

Gene therapy and gene correction: targets, progress, and challenges for treating human diseases

Current developments of gene therapy in human diseases

Viral vector platforms within the gene therapy landscape

Historic Overview of Genetic Engineering Technologies for Human Gene Therapy

Successes and challenges in clinical gene therapy

Genome-editing Technologies for Gene and Cell Therapy

Three decades of gene therapy development: milestones and prospects

Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord